Board summary
Key figures
84,164
Registered population
60.1% aged 18–64
18.8%
Aged 65+
ICB 19.9% · England 17.9%
10.0%
Ethnic minority (non-White)
4.9% Asian · England 9.6%
4.1%
In IMD quintile 1
ICB 17.1% · England 21.0%
~3,371
Core20 residents (est.)
Resident basis; registered basis ~3,402 · see page 3
12,108
Hypertension register
+4.62% in 3 yrs · England +5.60%
941
SMI register
72.8% of Tunbridge Wells'
1,249
COPD register
Reviews -0.05% in 3 yrs
Forecast to 2030
13,655
Hypertension patients, 2030
+1,547 on today
62.3%
QRISK ≥20% on statins, 2030
+3.11pp over 3 yrs
5.7%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
High-risk lipid therapy and BP control lag.
QRISK ≥ 20% lipid therapy is 55.6% (England 63.6%) and hypertension control is 64.3% (England 70.3%), which could reflect recall or escalation gaps.
Asthma and COPD annual reviews trail England.
Annual reviews reach 58.8% for asthma (England 65.7%; 2,038 unreviewed scale indicator) and 69.3% for COPD (England 76.4%), which may reflect recall gaps.
SMI physical checks and diabetes control lead.
SMI physical health checks reach 90.0% for BMI (England 82.1%) and 89.5% for BP (England 83.4%), alongside 59.4% non-frail diabetes HbA1c control.
Population, age and ethnicity
Aged 65+ patients reach 18.8% and aged 0-17 reach 21.1%, both above England
TUNBRIDGE WELLS PCN has a registered population of 84,164 patients. Among registered patients, 18.8% (15,821) are aged 65+, which is below Tunbridge Wells (20.2%) and NHS Kent and Medway ICB (19.9%) but above England (17.9%). Registered patients aged 0-17 represent 21.1% (17,768), compared with England (19.6%), Tunbridge Wells (21.0%), and NHS Kent and Medway ICB (20.7%). Projected population growth to 2030 (ONS) is 2.5% under an unverified projection methodology, compared with 2.3% for England, 5.3% for Tunbridge Wells, and 6.0% for NHS Kent and Medway ICB.
Age profile
65+: ICB 19.9%, England 17.9%
Ethnicity
Older people · falls rows are Tunbridge Wells local-authority (LA) data, not PCN
| Measure | Local | South East | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Tunbridge Wells LA) | 2,599 | 2,018 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 80.3% | 82.2% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 59.4% | 57.8% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Tunbridge Wells LA) | 1,454 | 981 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Tunbridge Wells LA) | 12.4 | 14.0 | 14.8 | 2022‑24 |
Deprivation and Core20
Core20 deprivation is 4.1% overall but spans 10.5 pp across member practices
Average IMD decile is 7.3 (Tunbridge Wells 6.8, NHS Kent and Medway ICB 5.4, England 5.5). The Core20 registered share is 4.1% against 2.7% in Tunbridge Wells, 17.1% in the ICB and 21.0% in England. Practice shares range by 10.5 pp: Speldhurst & Greggswood Medical Group has 10.5% (992 estimated patients), whereas Rusthall Medical Practice records 0.0%. The Wells Medical Practice has 6.7% and the largest volume (1,250 estimated patients). Practice counts and resident figures (3,371 people) use different population bases.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
941
SMI register
1.10% recorded prevalence
519
Learning disability register
0.61% recorded prevalence
25
Care homes, 1,165 beds
In the PCN catchment
7.9%
Provide unpaid care
Tunbridge Wells, Census 2021
The PCN records 941 patients on the severe mental illness register (1.1%) and 519 on the learning disability register (0.6%), alongside 25 care homes (1,165 beds) in its catchment. Borough estimates of unpaid carers (7.9%) and rough sleeping (1 in 2025) cannot be extrapolated to PCN registered patients.
Severe mental illness: physical health checks
Recorded SMI prevalence is 1.1% (941 patients). Among individual published checks, 89.5% had blood pressure recorded (England 83.4%) and 90.0% had BMI recorded (England 82.1%). Uncaptured elements mean these figures cannot confirm full physical health check completion.
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
12,108
Hypertension register
+4.62%
Register growth, 3 yrs
Tunbridge Wells +5.38% · England +5.60%
+0.45pp
BP control, under 80
≤140/90 · +1.26pp aged 80+
+1,547
More patients by 2030
Forecast 13,655 (15.50%)
Hypertension case-finding and control
Recorded hypertension prevalence is 14.2% (12,108 patients), below 14.8% in Tunbridge Wells, 16.2% in NHS Kent and Medway ICB and 15.2% in England, yielding an unadjusted register gap range of +356 to +710 patients. Recent blood pressure monitoring reaches 86.1%, trailing England (90.0%). Blood pressure treated to target is 64.3% overall and 59.7% among patients aged under 80, trailing England (70.3% and 67.8%). Slower identification and treatment control may indicate recall or titration shortfalls, unverified locally and testable via clinical audit. Lower treatment control than England leaves more diagnosed patients at cardiovascular risk, indicating that systematic recall and medication titration should be prioritised.
Lipids and statins
Lipid-lowering therapy reaches 55.6% for patients with QRISK ≥ 20% (England 63.6%) and 64.8% for primary prevention diabetes (England 73.2%). Adults aged 18+ receive 1,766 lipid items per 1,000, trailing England (4,100). Fewer at-risk patients receive lipid therapy than England, so recall audits should be prioritised.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 117,280 | £1.80 | £1.90 | £1.86 | £211,104 |
| Cardiovascular (all), 2025 | 160,502 | £3.94 | £3.57 | £3.33 | £632,378 |
For lipid-regulating drugs in 2026, the PCN prescribed 117,280 items at £1.80 per item, against £1.73 in Tunbridge Wells, £1.90 in NHS Kent and Medway ICB and £1.86 in England, spending £7,037 less than at England's unit cost. Unit cost is below England, so clinical teams can prioritise initiating therapy over formulary switching.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
+2.45%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
−1.15%
Asthma prevalence, PCN 3-yr % change
Asthma register prevalence is 6.1% (4,942 patients), where annual reviews reach 58.8%, trailing England (65.7%) and the ICB (60.4%), leaving about 2,000 unreviewed patients (2,038 scale indicator). Asthma prescribing for ages 5–19 is 1,109 items per 1,000 (England 1,488). COPD prevalence is 1.5% (1,249 patients), below England (1.9%), with reviews reaching 69.3% (England 76.4%, ICB 72.5%) after falling 0.1% over three years (England +2.8%). Slower review reach could reflect recall or capacity pressures, unverified locally and testable via recall audits.
Cancer register and children's immunisation
Cancer prevalence is 4.7% (3,975 patients), exceeding England (3.8%). Childhood immunisations achieve the 95.0% target for 12-month 6-in-1 (96.1%) and age-5 MMR1 (96.7%). However, age-5 MMR2 drops 6.9 pp to 89.8% (5.2 pp below target), and the 4-in-1 booster reaches 84.9% (10.1 pp below target). Pre-school booster attrition leaves children under-protected, consistent with recall or scheduling barriers, unverified locally and testable via audit.
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
55.6%
Kent and Medway ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~1,630
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Kent and Medway ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Breast | 82.1% | 85.4% | 23% | 1,509 |
| Prostate | 54.4% | 53.2% | 37% | 1,435 |
| Lung | 29.4% | 33.8% | 21% | 1,109 |
| Bowel | 48.2% | 47.0% | 29% | 1,013 |
| Skin cancer | 87.5% | 87.8% | 23% | 562 |
Cancer stage is not published at PCN level. In 2022, 55.6% of staged cancers in NHS Kent and Medway ICB were diagnosed at stage 1 or 2 (4,661 of 8,384 known-stage cases), slightly above England (55.3%) but 19.4 pp below the 75.0% national ambition. Known-stage completeness was 63.6% (8,384 of 13,189 registrations), trailing England (67.0%). Between 2013 and 2022, the ICB early-stage share increased by +2.2 pp. An estimated 1,627 additional early-stage diagnoses annually are required across the ICB to reach 75.0%. Across Tunbridge Wells PCN, cervical screening reached 69.7% (England 66.8%), though practice variation from 61.3% at Grosvenor & St James Medical Centre to 82.2% at Rusthall Medical Practice.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
Cancer waiting times describe wider system performance and are not published at PCN level. Maidstone and Tunbridge Wells NHS Trust met all three captured standards: 62-day referral to treatment was 2.4 pp above the 85.0% standard, 28-day faster diagnosis was 6.8 pp above the 75.0% standard, and 31-day treatment was 2.3 pp above the 96.0% standard. Across NHS Kent and Medway ICB, 62-day referral to treatment was below standard by 9.1 pp and 31-day treatment was below by 0.2 pp, while 28-day faster diagnosis was 1.8 pp above standard. Strong trust performance is consistent with prompt diagnostic turnaround, though provider.
| Pathways within standard (%) | Maidstone and Tunbridge Wells | King's College | Sussex | Kent and Medway ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 81.78 | 80.68 | 74.01 | 76.78 | 79.32 |
| 31-day treatment (96%) | 98.35 | 96.68 | 76.79 | 95.84 | 92.50 |
| 62-day referral to treatment (85%) | 87.43 | 70.15 | 65.20 | 75.93 | 71.16 |
| Diagnostic waits over 6 weeks (%) | Maidstone and Tunbridge Wells | King's College | Sussex | England |
|---|---|---|---|---|
| MRI | 0.92 | 21.22 | 5.62 | 21.40 |
| CT | 0.51 | 22.60 | 8.57 | 9.92 |
| Echocardiography | 2.57 | 14.39 | 0.39 | 28.48 |
| Colonoscopy | 19.80 | 41.81 | 39.35 | 30.83 |
| Gastroscopy | 24.03 | 35.98 | 20.02 | 29.02 |
| All 15 DM01 tests | 6.42 | 19.15 | 12.95 | 23.14 |
| Community services activity | Kent residents | Kent and Medway ICB |
|---|---|---|
| Care contacts | 210,170 | 254,055 |
| Referrals | 59,360 | 68,085 |
| Patients with a contact | 60,605 | 72,060 |
Community services (residents of Kent), Jun 2026 (provisional). Community contacts are reported for borough residents, not at PCN level. In Tunbridge Wells borough, adults aged 65 and over accounted for 65.8% of all community service contacts (138,250 of 210,170 contacts) in provisional Jun 2026 data. This concentration of contacts among older residents indicates that primary care coordination with community nursing may be valuable for managing older patients.
Practice variation and patient experience
Practice variation and patient experience
In 2025/26, England's overall QOF achievement was 92.5%. Across PCN practices, overall achievement ranged from 87.4% at The Wells Medical Practice to 97.1% at St Andrews Medical Centre. Vaccination achievement spanned 49.7 pp, from 29.8% at Lonsdale Medical Centre to 79.5% at St Andrews Medical Centre, against England's 55.2%. Variations may reflect documentation or call-recall differences, unverified locally.
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Rusthall Medical | 104 | 0.0 | 61.3% | 68.0% | 89.9% |
| Wells Medical | 116 | 6.7 | 41.1% | 84.5% | 86.6% |
| Grosvenor & St | 106 | 3.5 | 61.6% | 76.6% | 86.4% |
| Lonsdale | 104 | 4.1 | 67.0% | 74.8% | 86.2% |
| Kingswood Surgery | 106 | 2.1 | 60.2% | 76.6% | 84.1% |
| St Andrews | 115 | 1.1 | 60.5% | 64.1% | 77.9% |
| Waterfield House | 116 | 0.0 | 53.9% | 74.4% | 76.6% |
| Speldhurst & | 116 | 10.5 | 53.6% | 73.0% | 68.6% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Sixteen of 25 tracked measures lagged England's three-year trends despite notable preventive strengths
Across 25 tracked measures, 16 trailed England's three-year change. The widest relative lags occurred on the learning disability register (-0.1% vs +5.4% England) and stroke register (-2.5% vs +2.3% England), alongside COPD reviews (-0.1% vs +2.8% England). Conversely, three-year improvements outpaced England in psychosis alcohol recording (+14.5 pp vs +5.4 pp England), breast screening (+14.3% vs +8.4% England), and non-frail diabetes HbA1c control (+8.2% vs +4.4% England, where current achievement reached 59.4% vs 57.4% England).
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
Learning disability register
Stroke register
Dementia register
COPD reviews
Depression register
Alcohol record (psychosis)
Breast screening (53-70)
Diabetes HbA1c control
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Tunbridge Wells | Asset | PCN | Tunbridge Wells |
|---|---|---|---|---|---|
| Care homes (catchment) | 25 (1,165 beds) | n/a | Schools (catchment) | 74 | n/a |
| Children's centres | 4 | 6 | Places of worship | 62 | 89 |
| Libraries | 7 | 9 | Food banks (VCS) | 2 | 2 |
| Homelessness support (VCS) | n/a | 1 | Day centres (VCS) | 4 | 5 |
| Children and young people (VCS) | n/a | 2 | Carers support groups (VCS) | 3 | 4 |
| Primary schools (LA maintained) | 18 | 24 | Primary academies | 5 | 7 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Hypertension and lipid escalation
On the 12,108 hypertension register (14.2%, modelled gap +356 to +710), BP control is 64.3% (England 70.3%) and QRISK ≥ 20% lipid therapy is 55.6% (England 63.6%). For discussion: practices could run pharmacist-led recall and titration clinics for uncontrolled hypertension and untreated QRISK ≥ 20% cohorts, alongside opportunistic BP checks. Moderate effort to run.
Evidence base: the hypertension register is the cohort for case-finding, blood-pressure control and AF anticoagulation; its size and growth set the workload those interventions must cover, and a shortfall in control shows up later as emergency admission.
Policy anchor: Core20PLUS5 (hypertension case-finding and optimal management); NHS CVD ambitions to 2029 on detection, treatment to target and statins for high-risk patients (CVDPREVENT).
Option 2
Structured asthma review recall
Asthma review coverage is 58.8% on the 4,942 register, behind England (65.7%) by 6.9 pp and NHS Kent and Medway ICB (60.4%) by 1.7 pp, with 2,038 unreviewed (about 2,000). Low cost, quick to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Option 3
COPD review and case-finding audit
Recorded COPD prevalence is 1.5% (1,249 patients; modelled gap +75 to +345 against Tunbridge Wells and England), while annual reviews reach 69.3% (England 76.4%, ICB 72.5%). Moderate effort to run.
Evidence base: the copd register is the cohort for spirometry-confirmed diagnosis, annual review and inhaler technique; register size and growth set the workload those interventions must cover.
Policy anchor: Core20PLUS5 adults: chronic respiratory disease (COPD vaccination and exacerbation reduction); Tobacco and Vapes Bill: smokefree generation.
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Older cohort capacity review (p2) | Aged 65+ | Neighbourhood health framework · NHS vaccination strategy | PCN |
| Dual track deprivation outreach (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| Hypertension blood pressure control review (p5) | Last BP reading of patients (<80 yrs with hypertension) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Pre-school booster catch-up recall (p6) | MMR dose 2 coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Cervical screening recall audit (p7) | Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs) | Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026 | PCN |
| Option 1 · Hypertension and lipid escalation (p12) | Hypertension register · Hypertension: QOF prevalence · Hypertension patients treated to target | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Option 2 · Structured asthma review recall (p12) | Asthma register · Asthma: QOF prevalence · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) | Core20PLUS5 respiratory | PCN |
| Option 3 · COPD review and case-finding audit (p12) | COPD register · COPD: QOF prevalence · COPD patients with a review in the last 12 months | Core20PLUS5 approach · Tobacco and Vapes Bill | PCN |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | ICB | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
